CCCCHealthcare · BiotechnologyThe 9 Wall Street analysts covering C4 Therapeutics, Inc. hold a median 12-month price target of $11 — +211.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 31 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores C4 Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (90): Sales and profits are climbing, and climbing faster than before.
Volatility (17): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CCCC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +211.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Oct 2026 | JP Morgan | Initiates | Overweight | $10 |
| 1 June 2026 | Evercore ISI Group | Maintains | Outperform | $7.00 → $12 |
| 1 June 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 27 Feb 2026 | Barclays | Maintains | Overweight | — |
| 23 Feb 2026 | Brookline Capital | Maintains | Buy | — |
| 17 Dec 2025 | Barclays | Maintains | Overweight | — |
| 2 Dec 2025 | TD Cowen | Initiates | Buy | — |
| 23 Sept 2025 | Barclays | Maintains | Overweight | — |
| 23 Sept 2025 | Wells Fargo | Maintains | Overweight | — |
| 22 Sept 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 17 Sept 2025 | Barclays | Initiates | Overweight | — |
| 15 Sept 2025 | Stephens & Co. | Upgrade | Overweight | — |
| 4 Sept 2025 | Guggenheim | Initiates | Buy | — |
| 19 Dec 2024 | Wells Fargo | Upgrade | Overweight | — |
| 18 Nov 2024 | Stephens & Co. | Initiates | Equal-Weight | — |
| 6 Aug 2024 | BMO Capital | Reiterates | Outperform | — |
| 9 May 2024 | Stifel | Maintains | Buy | — |
| 9 May 2024 | Wells Fargo | Maintains | Equal-Weight | — |
| 26 Feb 2024 | Morgan Stanley | Maintains | Equal-Weight | — |
| 23 Feb 2024 | Stifel | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CCCC appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, C4 Therapeutics, Inc. returned +37.0% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 87% of US stocks
Cheaper than 12% of US stocks
Cheaper than 49% of US stocks
Cheaper than 74% of US stocks
Higher than 34% of US stocks
Higher than 40% of US stocks
Higher than 8% of US stocks
Higher than 1% of US stocks
Higher than 22% of US stocks
Higher than 20% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
C4 Therapeutics, Inc. has a market value of $414.6M and an enterprise value of $209.2M.
Revenue in the twelve months to 30 June 2026: $35.0M. The latest quarter grew 2.8% year on year.
Net income over the same four quarters: −$101.4M, a −289.4% net margin.
Diluted earnings per share, trailing twelve months: $−1.00.
Free cash flow in the twelve months to 30 June 2026: −$85.4M.
C4 Therapeutics, Inc. spent $238K on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: −2.7×; forward P/E: −3.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
C4 Therapeutics, Inc. employs 104 people — $337K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own C4 Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research says C4 Therapeutics has a combination of factors it views as supporting a likely earnings beat in the company’s upcoming Q3 report, and outlines key expectations ahead of the release.
Why it matters — The item presents an earnings outlook that CCCC watchers may consider ahead of the Q3 report.
C4 Therapeutics said it highlighted a DNA-encoded library at the 9th Annual Targeted Protein Degradation Summit. The platform combines its cereblon-binding ligand library with screening capabilities to support target-first identification of molecular glue degraders.
Why it matters — The presentation describes an expansion of C4T’s discovery-platform capabilities relevant to its targeted protein degradation research.
Insmed announced that Paul Hudson, former CEO of Sanofi and Novartis Pharmaceuticals, and Utpal Koppikar, CFO of Verily Health, have joined its board as independent directors, effective immediately.
Why it matters — The announcement concerns Insmed rather than C4 Therapeutics, so it has no direct company-specific implication for CCCC based on the provided text.
C4 Therapeutics presented new biomarker data from its Cemsidomide Phase 1 trial with dexamethasone and Phase 1b trial with elranatamab in relapsed/refractory multiple myeloma at the 23rd International Myeloma Society Annual Meeting. The data demonstrated robust T-cell activation, a key component of cemsidomide's dual mechanism of action.
Why it matters — This presentation provides evidence supporting cemsidomide's mechanism of action in treating relapsed/refractory multiple myeloma, offering C4 Therapeutics watchers insight into the drug's clinical development progress.
This Zacks Investment Research article compares how C4 Therapeutics (CCCC) and MacroGenics (MGNX) have performed against their sector so far this year, framing the question of whether medical stocks are lagging C4 Therapeutics.
Why it matters — A C4 Therapeutics watcher would use this comparison to gauge how the company's year-to-date performance stacks up against both a peer and its broader sector.
The 9 Wall Street analysts covering C4 Therapeutics, Inc. have a median 12-month price target of $11, with estimates ranging from $7 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering C4 Therapeutics, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks C4 Therapeutics, Inc. 69 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, C4 Therapeutics, Inc. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (90 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +211.6% from the last close, and Ticker Nerd's factor model ranks C4 Therapeutics, Inc. 69 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering C4 Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CCCC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $30 over the next 12 months.
C4 Therapeutics, Inc. returned +37.0% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation, a drug-development approach designed to eliminate disease-causing proteins rather than only blocking their activity.
The most recent item we track (Zacks Investment Research, 29 Oct 2026): "C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release". Zacks Investment Research says C4 Therapeutics has a combination of factors it views as supporting a likely earnings beat in the company’s upcoming Q3 report, and outlines key expectations ahead of the release.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation, a drug-development approach designed to eliminate disease-causing proteins rather than only blocking their activity. The company develops small-molecule medicines built on its proprietary TORPEDO platform, which is used to design and optimize degraders for difficult-to-treat diseases. Its current pipeline is centered on oncology, with programs aimed at cancers such as multiple myeloma, lymphoma, melanoma, colorectal cancer, and non-small cell lung cancer. C4 Therapeutics also works through strategic collaborations with other biopharmaceutical companies to expand the reach of its technology and advance new therapeutic candidates. Based in Watertown, Massachusetts, C4 Therapeutics plays a specialized role in the biotechnology market by advancing a next-generation therapeutic modality that seeks to address targets and pathways not readily handled by traditional small-molecule drugs.
CEO Mr. Andrew J. Hirsch M.B.A. · 104 employees · United States · https://www.c4therapeutics.com
